Stay updated with breaking news from Trials Network. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New York Blood Center’s Project ACHIEVE and Columbia University’s Columbia Research Unit are working in partnership for the New York City effort to advance the use of messenger ribonucleic acid (mRNA) technology in an HIV preventive vaccine study – HVTN 302.
In today's Research Roundup for March 21, 2022, we highlight some of the most interesting reads in global health research and development from the past week.
Three potential HIV vaccines developed by Moderna have entered clinical trials, the National Institutes of Health (NIH) has confirmed.
Phase 1 study is among first to examine mRNA technology for HIV.
The National Institute of Allergy and Infectious Diseases (NIAID) has launched Phase 1 clinical trial to evaluate experimental HIV vaccines.